CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients

Lara Chavaz; Léna Royston; Stavroula Masouridi-Levrat; Anne-Claire Mamez; Federica Giannotti; Sarah Morin; Christian Van Delden; Yves Chalandon; Dionysios Neofytos

doi:10.1093/ofid/ofad169

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients

Open Forum Infect Dis. 2023 Mar 27;10(4):ofad169. doi: 10.1093/ofid/ofad169. eCollection 2023 Apr.

Authors

Lara Chavaz¹, Léna Royston¹, Stavroula Masouridi-Levrat², Anne-Claire Mamez², Federica Giannotti², Sarah Morin², Christian Van Delden¹, Yves Chalandon², Dionysios Neofytos¹

Affiliations

¹ Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland.
² Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and faculty of Medicine, University of Geneva, Geneva, Switzerland.

Abstract

In this single-center study of 61 allogeneic hematopoietic cell transplant (HCT) recipients receiving letermovir primary cytomegalovirus (CMV) prophylaxis for the first 100 days, we report 23% incidence of clinically significant CMV infection during the first 100 days after letermovir discontinuation, predominately in haploidentical HCT recipients, without any associations with CMV-DNAemia under letermovir.

Keywords: allogeneic hematopoietic cell transplant recipients (allo-HCTr); breakthrough infection; cytomegalovirus (CMV); letermovir; prophylaxis; risk factors.